Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called ...

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

The agreement announced Wednesday includes sweeping changes to the Cigna PBM’s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and ...